BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7544232)

  • 1. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
    Lygidakis NJ; Kosmidis P; Ziras N; Parissis J; Kyparidou E
    J Interferon Cytokine Res; 1995 May; 15(5):467-72. PubMed ID: 7544232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.
    Lygidakis NJ; Pothoulakis J; Konstantinidou AE; Spanos H
    Anticancer Res; 1995; 15(2):543-50. PubMed ID: 7539237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours.
    Lygidakis NJ; Savanis G; Pothoulakis J; Kapetanakis A
    Anticancer Res; 1994; 14(2B):643-6. PubMed ID: 8010721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.
    Lygidakis NJ; Konstantinidou T; Pothoulakis J
    Anticancer Res; 1994; 14(3B):1351-5. PubMed ID: 8067704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
    Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
    Tanaka K; Yabushita Y; Nakagawa K; Kumamoto T; Matsuo K; Taguri M; Endo I
    Eur J Surg Oncol; 2013 Dec; 39(12):1364-70. PubMed ID: 24183169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case report of hepatocellular carcinoma with hepatic and portal venous tumor thrombus and multiple intrahepatic metastasis who survived over 1 year after the operation with combined locoregional chemotherapy].
    Shimizu J; Nagano H; Sakon M; Dono K; Takeda Y; Kishimoto S; Eguchi H; Miyamoto A; Kondo M; Nakamori S; Umeshita K; Nakamura H; Wakasa K; Monden M
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1895-9. PubMed ID: 10560420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
    Lin CP; Yu HC; Cheng JS; Lai KH; Lo GH; Hsu PI; Lin CK; Chen HH; Lo CC; Liang HL; Tseng HH
    J Chin Med Assoc; 2004 Dec; 67(12):602-10. PubMed ID: 15779483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma.
    Lygidakis NJ; Ziras FA; Kyparidou E; Parissis J; Papadopoulou P; Venetsanou B
    Hepatogastroenterology; 1995; 42(6):1039-52. PubMed ID: 8847017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
    Ishida K; Hirooka M; Hiraoka A; Kumagi T; Uehara T; Hiasa Y; Horiike N; Onji M
    Jpn J Clin Oncol; 2008 Sep; 38(9):596-603. PubMed ID: 18772170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
    Hwang JY; Jang BK; Kwon KM; Chung WJ; Park KS; Cho KB; Hwang JS; Ahn SH; Kim GC; Kim YH; Choi JS; Kwon JH
    Korean J Gastroenterol; 2005 Feb; 45(2):118-24. PubMed ID: 15725716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional immunochemotherapy in hepatocellular carcinoma.
    Kountouras J; Boura P; Kouklakis G
    Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma].
    Miura T; An M; Matsumoto Y; Terakado H; Murata M; Takagi S; Ikawa M; Hamada E; Watanabe K; Nakasato S
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1262-5. PubMed ID: 9703803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic artery chemotherapy-embolization and biological response modifiers for late hepatic carcinoma].
    Ji T; Sun J; Gu Q
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):129-31. PubMed ID: 7656804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study.
    Lygidakis NJ; Stringaris K; Kokinis K; Lyberopoulos K; Raptis S
    Hepatogastroenterology; 1996; 43(7):212-20. PubMed ID: 8682466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.
    Ito T; Ikeda N; Sue K; Ukida M; Higashi T; Okamoto T; Ohsawa T; Nouso K; Watanabe A; Tsuji T
    Gastroenterol Jpn; 1989 Aug; 24(4):386-92. PubMed ID: 2476356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
    Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.